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EDITORIAL COMMENT
Confusion in Reperfusion*
C. Michael Gibson, MS, MD, FACC
Boston, Massachusetts
In this issue of the Journal, Dubois et al. (1) evaluate the
clinical outcomes among patients treated with urgent or
elective percutaneous intervention (PCI) after pharmacologic
reperfusion with tenecteplase combined with unfractionated
heparin, enoxaparin, or abciximab. The data presented here
indicate that treatment with the glycoprotein (GP) IIb/IIIa
inhibitor abciximab (ReoPro, Centocor Inc., Malvern, Penn-
sylvania) is associated with poorer clinical outcomes, including
a higher mortality rate at one year. These results stand in
contrast to trials, such as ADMIRAL, in which clinical
benefits were observed with the administration of abciximab in
the absence of fibrinolytic agents (2). Such divergent outcomes
can at times lead to what I call “confusion in reperfusion.” A
careful review of differences in trial design and methodology
are needed to reconcile such disparate outcomes across well-
designed and well-conducted clinical trials.
See page 1178
The Assessment of the Safety and Efficacy of a New
Thrombolytic Regimen (ASSENT-3) authors examined
the clinical outcomes among patients treated with PCI after
fibrinolytic monotherapy or low-dose fibrinolytic coupled
with full-dose abciximab administration. The frequency of
urgent PCI in the trial was low (15%); this is in keeping
with the equipoise regarding the clinical benefit of perform-
ing PCI shortly after fibrinolytic administration (3–6).
Early trials in the era of conventional balloon angioplasty
suggested that clinical outcomes were actually poorer among
patients treated with rescue or adjunctive PCI after fibrino-
lysis, largely because of a heightened risk of abrupt closure
secondary to hemorrhage into the vasa vasorum of the vessel
wall (3,4). However, in the modern era of intracoronary
stent placement, thienopyridine, and GP IIb/IIIa inhibitor
use, the results may now be different (7–9). It is difficult to
answer the question regarding the potential benefit of rescue
and adjunctive PCI after fibrinolytic administration because
of reluctance on the part of operators to randomize patients
to a strategy of observing a closed artery (6). Nonrandom-
ized retrospective data from the era of intracoronary stent
placement and modern pharmacologic therapy does suggest
a benefit in two-year mortality from either rescue (opening
of a closed artery) or adjunctive PCI (mechanical interven-
tion if the artery is patent) (8). A likely mechanism of
benefit in these patients appears to be a reduction in
reinfarction, which is associated with a doubling in mortal-
ity (9). Indeed, it is this risk of reinfarction and the risk of
intracranial hemorrhage (ICH) that likely account for dif-
ferences in mortality between fibrinolytic and primary PCI
strategies, particularly because fibrinolytic strategies may
achieve patency more rapidly, albeit less fully.
In the ASSENT-3 trial, GP IIb/IIIa inhibition was
administered concurrently with half-dose fibrinolysis. The
ASSENT-3 data do not address the safety or efficacy of the
delayed administration of GP IIb/IIIa inhibition after
full-dose fibrinolysis. Although there are no randomized
data to address this issue, a recent meta-analysis involving
3,418 patients undergoing adjunctive PCI in the
ASSENT-1, -2, and -3, Global Utilization of Strategies To
Open occluded arteries (GUSTO)-III and -V, Thrombol-
ysis In Myocardial Infarction (TIMI)-10B and -14, Intra-
venous nPA for Treatment of Infarcting Myocardium Early
(In-TIME)-2, Strategies for Patency Enhancement in the
Emergency Department (SPEED), Fibrinolytic and Aggra-
stat ST-elevation Resolution Trial (FASTER), Enoxaparin
as Adjunctive Antithrombin Therapy for ST-Elevation
Myocardial Infarction (ENTIRE)-TIMI-23, and Integ-
rilin and Tenecteplase in Acute Myocardial Infarction
(INTEGRITI) trials was presented at the 2003 American
College of Cardiology meeting, and the results are in
contrast with those observed in ASSENT3 (10). In this
post-hoc, nonrandomized analysis, all patients received full-
dose fibrinolytic monotherapy. The risk of moderate bleeding
by the GUSTO criteria was increased by 0.6% (7.1% vs. 6.5%,
odds ratio [OR] 1.47, 95% confidence interval [CI] 1.07 to
2.02) as was the risk of moderate-to-severe bleeding (10.2% vs
8.1%, OR 1.64, 95% CI 1.24 to 2.16). The risk of death
tended to be lower among patients who underwent PCI within
24 h of presentation who were treated with a GP IIb/IIIa
inhibitor (4.6%, n 1,032 vs. 6.6%, n 2,386, OR 0.71, 95%
CI 0.49 to 1.01). In this meta-analysis, the use of PCI and GP
IIb/IIIa inhibitors was not randomized; therefore, unmeasured
treatment biases may have again confounded outcomes. In
contrast with the ASSENT-3 trial, patients in the meta-
analysis received a variety of GP IIb/IIIa inhibitors (abciximab,
eptifibatide, and tirofiban) and a variety of fibrinolytic agents
(alteplase, reteplase, and tenectaplase). Obviously, the timing
of GP IIb/IIIa inhibition in relation to the fibrinolytic admin-
istration may play a role in bleeding complications, and this
was not adjusted for in the analysis.
It should also be borne in mind that although currently
available fibrinolytic agents all have a relatively short half-
life, rt-PA administration, and to a lesser extent non-
recombinant tissue-type plasminogen activator (t-PA) ad-
ministration, may result in significant fibrinogen depletion
that may persist for up to 12 h (11), extending the biologic
half-life of the agent and the risk of bleeding. Given the
limited data that are available, the risks and benefits in the
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administration of full-dose GP IIb/IIIa inhibition after
full-dose fibrinolytic administration must be weighed care-
fully. Patients who are at high risk of ICH include the
elderly, females, patients with low body weights, and hy-
pertensive patients. Consideration should also be given to
whether the patient received an agent that depletes fibrin-
ogen, such as r-PA and, to a lesser degree, t-PA. A stat
fibrinogen level can be checked to ascertain whether the
fibrinogen level is above 100, a threshold below which there
are data to suggest an increase in bleeding risk (12). Those
patients with limited benefit might include patients who
present late with low-risk anatomy, such as hemodynami-
cally stable inferior infarction.
Data from the ASSENT-3 trial also do not address the
efficacy of GP IIb/IIIa administration alone before PCI.
Administration of abciximab in the cardiac catheterization
laboratory was associated with a modest reduction in events
in the Controlled Abciximab and Device Investigation to
Lower Late Angioplasty Complications (CADILLAC)
trial (13). It should be noted that not all patients in the
CADILLAC trial had ST-segment elevation and that the
trial population may have included some lower risk patients,
as demonstrated by the 1% to 2% mortality in this trial (13).
Earlier administration of abciximab was associated with
improved clinical outcomes in the ADMIRAL trial (2), an
effect that appeared to be mediated by improved angio-
graphic outcomes. Likewise, angiographic data from the
randomized TIGER-PA trial of pre-PCI tirofiban (14) and
case-control data from the RAPIER study of eptifibatide (15)
indicate that these agents also improve TIMI flow grades,
frame counts, and perfusion grades before primary PCI.
The ASSENT-3 authors were careful to control for
known confounders and performed a detailed propensity
analysis. Despite their careful efforts, unidentified con-
founders may have influenced the mortality observations.
The ASSENT-3 was an open-label trial and PCI was
performed at the discretion of the treating physician. Fewer
patients who received abciximab underwent urgent PCI,
indicating that these were potentially a more select group of
patients. It is entirely possible that those patients treated
with abciximab were sicker. Chance could also have played
a role in the findings given that 46 comparisons were made.
Of the 46 comparisons, 3 were positive and 2 of the
significant results pertained to increased bleeding, which are
biologically plausible findings.
In contrast with the data presented here from the
ASSENT-3 study (in which a minority of patients under-
went urgent PCI), planned and ongoing trials of facilitated
PCI strategies will instead require that all patients undergo
PCI (predominantly urgent) after pharmacologic therapy.
Mechanical intervention in all patients will greatly reduce the
potential selection bias that is inherent to any retrospective
analysis. These future trials should provide important prospec-
tive randomized data by which to compare the efficacy of a
variety of pharmacologic regimens, and hopefully lend some
clarity to any ongoing confusion in reperfusion.
Reprint requests and correspondence: Dr. C. Michael Gibson,
Director, TIMI Data Coordinating Center, 350 Longwood
Avenue, First Floor, Boston, Massachusetts 02115. E-mail:
mgibson@timi.org.
REFERENCES
1. Dubois CL, Belmans A, Granger CB, et al., on behalf of the
ASSENT-3 Investigators. Outcome of urgent and elective percutane-
ous coronary interventions after pharmacologic reperfusion with te-
necteplase combined with unfractionated heparin, enoxaparin, or
abciximab. J Am Coll Cardiol 2003;42:1178–85.
2. Montalescot G, Barragan P, Wittenberg O, et al., for the ADMIRAL
Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary
stenting for acute myocardial infarction. N Engl J Med 2001;344:
1895–903.
3. Simoons ML, Beitriu A, Col J, et al. Thrombolysis with tissue
plasminogen activator in acute myocardial infarction: no additional
benefit from immediate percutaneous coronary intervention. Lancet
1988;1:197–203.
4. TIMI Study Group. Comparison of invasive and conservative strate-
gies after treatment with intravenous tissue plasminogen activator in
acute myocardial infarction. Results of the Thrombolysis In Myocar-
dial Infarction (TIMI) phase II trial. N Engl J Med 1989;320:618–27.
5. Gibson CM, Cannon CP, Greene RM, et al., for the TIMI 4 Study
Group. Rescue PCI in the Thrombolysis In Myocardial Infarction
(TIMI) 4 trial. Am J Cardiol 1997;80:21–6.
6. Ellis SG, Ribeiro da Silva E, Heyndrickx G, et al., for the RESCUE
Investigators. Randomized comparison of rescue PCI with conserva-
tive management of patients with early failure of thrombolysis for acute
anterior myocardial infarction. Circulation 1994;90:2280–4.
7. Ross AM, Coyne KS, Reiner JS, et al., for the PACT Investigators. A
randomized trial comparing primary PCI with a strategy of short-
acting thrombolysis and immediate planned rescue PCI in acute
myocardial infarction: the PACT trial. J Am Coll Cardiol 1999;34:
1954–62.
8. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV,
Braunwald E, for the TIMI Study Group. Relationship of the TIMI
myocardial perfusion grades, flow grades, frame count, and percuta-
neous coronary intervention to long-term outcomes after thrombolytic
administration in acute myocardial infarction. Circulation 2002;105:
1909–13.
9. Gibson CM, Karha J, Murphy SA, et al., for the TIMI Study Group.
Early and long-term clinical outcomes associated with reinfarction
following fibrinolytic administration in the Thrombolysis In Myocar-
dial Infarction trials. J Am Coll Cardiol 2003;42:7–16.
10. Roe MT, Giugliano RP, Tuttle R, et al. Safety of adjunctive
glycoprotein IIb/IIIa blockade during rescue/early percutaneous coro-
nary intervention following full-dose fibrinolytic therapy for acute
myocardial infarction (abstr). J Am Coll Cardiol 2003;41 Suppl
A:332A.
11. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and
stable coronary thrombolysis with bolus administration of reteplase
compared with alteplase infusion in acute myocardial infarction.
RAPID Investigators. Circulation 1995;91:2725–32.
12. Meierhenrich R, Carlsson J, Seifried E, et al. Effect of reteplase on
hemostasis variables: analysis of fibrin specificity, relation to bleeding
complications and coronary patency. Int J Cardiol 1998;65:57–63.
13. Stone GW, Grines CL, Cox DA, et al. Controlled Abciximab and
Device Investigation to Lower Late Angioplasty Complications
(CADILLAC) Investigators. Comparison of angioplasty with stent-
ing, with or without abciximab, in acute myocardial infarction. N Engl
J Med 2002;346:957–66.
14. Lee DP, Herity NA, Hiatt BL, et al. Adjunctive platelet glycoprotein
IIb/IIIa receptor inhibition with tirofiban before primary angioplasty
improves angiographic outcomes: results of the Tirofiban Given in the
Emergency Room before Primary Angioplasty (TIGER-PA) pilot
trial. Circulation 2003;107:1497–501.
15. Cutlip DE, Cove CJ, Irons D, et al. Emergency room administration
of eptifibatide before primary angioplasty for ST elevation acute
myocardial infarction and its effect on baseline coronary flow and
procedure outcomes. Am J Cardiol 2001;88:62–4.
1187JACC Vol. 42, No. 7, 2003 Gibson
October 1, 2003:1186–7 Editorial Comment
